5.20
-0.07 (-1.33%)
| Previous Close | 5.27 |
| Open | 5.25 |
| Volume | 498,652 |
| Avg. Volume (3M) | 3,560,764 |
| Market Cap | 357,490,752 |
| Price / Book | 2.73 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -3.14 |
| Total Debt/Equity (MRQ) | 19.91% |
| Current Ratio (MRQ) | 4.95 |
| Operating Cash Flow (TTM) | -82.77 M |
| Levered Free Cash Flow (TTM) | -46.26 M |
| Return on Assets (TTM) | -40.84% |
| Return on Equity (TTM) | -75.45% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | PepGen Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.88 |
|
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.27% |
| % Held by Institutions | 95.95% |
| 52 Weeks Range | ||
| Median | 20.00 (284.62%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 13 Nov 2025 | 20.00 (284.62%) | Buy | 4.89 |
| 27 Oct 2025 | 18.00 (246.15%) | Buy | 5.43 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Dec 2025 | Announcement | PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer |
| 08 Dec 2025 | Announcement | PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer |
| 12 Nov 2025 | Announcement | PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule |
| 12 Nov 2025 | Announcement | PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights |
| 03 Nov 2025 | Announcement | PepGen to Participate in Upcoming Investor Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |